Skip to main content

JHU specific antibodies

CANCER RESEARCH TECHNOLOGY LIMITED
TERMS AND CONDITIONS FOR SUPPLY OF ANTIBODY

1. DEFINITIONS

ANTIBODY means the antibody to be supplied by CANCERTOOLS.ORG to the PURCHASER under this contract

CR-UK means Cancer Research UK a company registered under number 4325234 and registered charity number 1089464 and with its registered office at 2 Redman Place, London, E20 1JQ, UK.

CANCERTOOLS.ORG means Cancer Research Technology Limited a company registered in England under number 1626039 and with its registered office at 2 Redman Place, London, E20 1JQ, UK, and its successors and assigns.

PURCHASER means the organisation or person (which shall include any organisation or a person who purchases on behalf of) who buys the CELL LINE from CANCERTOOLS.ORG.

RESEARCH PURPOSES means academic, non-commercial, experimental research purposes only and excludes any (i) research or testing involving human subjects and (ii) therapeutic or diagnostic purposes.

SOURCE means Johns Hopkins University.

MODIFIED ANTIBODY means any materials generated by the PURCHASER that contain or incorporate the ANTIBODY.

2. CONTRACT TERMS

2.1 Orders for ANTIBODY raised by the PURCHASER are subject to written acceptance by CANCERTOOLS.ORG.

2.2 Acceptance of the ANTIBODY by the PURCHASER shall be deemed conclusive evidence of the PURCHASER’s acceptance of the conditions of sale set out in this contract.

2.3 Unless other terms and conditions are expressly accepted by CANCERTOOLS.ORG by means of a specific amendment hereto signed by CANCERTOOLS.ORG, all orders and contracts for supply of ANTIBODY will be on these terms and conditions to the exclusion of any other terms and conditions whether or not endorsed upon or referred to in any purchase order or otherwise.

2.4 The Uniform Laws on International Sales Act 1967 shall not apply to this contract.

2.5 Any quotation is valid for a period of thirty (30) days only from its date provided that CANCERTOOLS.ORG has not previously withdrawn it.

3. ORDER QUANTITIES

3.1 The PURCHASER acknowledges that polyclonal ANTIBODY is a non- renewable resource and of limited availability. The PURCHASER acknowledges that acceptance of all orders is subject to availability.

3.2 Unless expressly stated otherwise in this contract, all prices shall be exclusive of Value Added Tax and any customs, duties or other taxes, for which the PURCHASER will be additionally liable

4. TERMS OF PAYMENT

4.1 CANCERTOOLS.ORG, by written notice, will require payment for ANTIBODY and if required shipping costs, in advance of delivery. The payment will be made by the PURCHASER in full without any deductions and before any shipment of ANTIBODY is made. All payments shall be made in Pounds Sterling, unless otherwise agreed by CANCERTOOLS.ORG. Payment shall be made by either:

a) WorldPay credit/debit card payment link service; or
b) BACS payment.

4.2 Only in instances where CANCERTOOLS.ORG has agreed an account with the PURCHASER, will the price become payable on delivery.

4.3 Pursuant to Clause 4.1b, if the PURCHASER fails to settle any invoice in full on the due date, then without prejudice to any other right or remedy of CANCERTOOLS.ORG, CANCERTOOLS.ORG shall be entitled to:

a) charge interest from the date of the invoice until payment at an annual rate of four percent (4%) above the annual base rate of the Bank of England (or its successor) from time to time (or, if lower, the maximum interest rate permitted by applicable law); and
b) suspend deliveries of ANTIBODY until payment has been received by CANCERTOOLS.ORG.

4.4 If the PURCHASER fails to pay in full then the order will be cancelled, and the delivery of ANTIBODY will be suspended.

5. DELIVERY

5.1 ANTIBODY will be delivered by CANCERTOOLS.ORG’s UK production and storage premises and risk in and to the ANTIBODY will pass to the PURCHASER on delivery.

5.2 The PURCHASER shall make all arrangements necessary to take delivery of the ANTIBODY whenever they are tendered for delivery by CANCERTOOLS.ORG.

5.3 On request and by CANCERTOOLS.ORG’s written acceptance of such request, CANCERTOOLS.ORG shall arrange transport of ANTIBODY to the PURCHASER but all costs and risk associated therewith shall be borne by the PURCHASER.

5.4 CANCERTOOLS.ORG will use its reasonable endeavours to meet any agreed date for delivery of the ANTIBODY, but in no circumstances shall CANCERTOOLS.ORG have any liability for loss or damage of any kind whatsoever caused directly or indirectly by any delay in delivery of the ANTIBODY nor unless such delay exceeds sixty (60) days will any delay entitle PURCHASER to cancel or terminate this contract.

5.5 If the PURCHASER fails to accept delivery of ANTIBODY on the delivery date stipulated by CANCERTOOLS.ORG or within 3 days of notification that ANTIBODY is ready for dispatch, CANCERTOOLS.ORG reserves the right to request that the PURCHASER shall pay reasonable storage charges or demurrage as appropriate in the circumstances until the ANTIBODY are either dispatched to the PURCHASER or disposed of elsewhere.

6. USE OF THE ANTIBODY

6.1 ANTIBODY and MODIFIED ANTIBODY shall be used solely for RESEARCH PURPOSES. The PURCHASER shall procure that all persons to whom the PURCHASER makes the ANTIBODY available are made aware of and comply with these provisions.

6.2 Save for the limited right for the PURCHASER to use the ANTIBODY and any MODIFIED ANTIBODY for RESEARCH PURPOSES only (the “RESEARCH”), no licence is granted or implied under any intellectual property or other rights of CANCERTOOLS.ORG. The PURCHASER acknowledges and agrees that it has no right, title or interest whatsoever in the ANTIBODY and that as between the PURCHASER and CANCERTOOLS.ORG the same shall vest or remain vested in CANCERTOOLS.ORG absolutely.

6.3 Right, title and interest in the MODIFIED ANTIBODY shall vest in the PURCHASER, except that CANCERTOOLS.ORG or CANCERTOOLS.ORG’s licensors shall retain ownership of all rights, title and interest in the ANTIBODY.

6.4 Right, title and interest in the results arising from the RESEARCH shall belong to the PURCHASER.

6.5 If, as a result of its RESEARCH, the PURCHASER identifies potential commercial applications of the ANTIBODY or MODIFIED ANTIBODY, the PURCHASER will promptly inform CANCERTOOLS.ORG in writing. In the event that a MODIFIED DERIVATIVE is commercially exploited by the PURCHASER or agents acting on behalf of the PURCHASER, CANCERTOOLS.ORG shall be entitled to an equitable share of any revenues that accrue to the PURCHASER from such commercial exploitation, having regard to the significance of the contribution of ANTIBODY. The Purchaser is not permitted to commercially exploit any materials or invention containing the ANTIBODY without CANCERTOOLS.ORG’s prior written permission.

6.6 At CANCERTOOLS.ORG’s request, the PURCHASER shall discuss in good faith a worldwide, sub-licensable licence on fair and reasonable terms under all intellectual property rights in the MODIFIED ANTIBODY for all purposes.

6.7 PURCHASER shall keep CANCERTOOLS.ORG fully informed of any published results which pertain to modifications, improvements or new uses of ANTIBODY within ninety (90) days of publication.

6.8 The PURCHASER shall fully acknowledge the SOURCE of the ANTIBODY (quoting the CANCERTOOLS.ORG’s catalogue reference number) and ensure that accurate reference is made to the work of the original depositor, in all publications and presentations relating to the RESEARCH. ANTIBODY and MODIFIED ANTIBODY shall be used solely by the PURCHASER and those within the PURCHASER’s immediate research group only who are under the PURCHASER’s direct supervision. PURCHASER shall not make ANTIBODY available to any persons or organisations outside of the PURCHASER’s immediate research group at the time of purchase and shall ensure that ANTIBODY is not taken or sent to any location other than the PURCHASER’s laboratory.

6.9 The PURCHASER shall not resell, sub-license or distribute the ANTIBODY and the PURCHASER shall not purport to be a reseller or distributor of ANTIBODY on behalf of CANCERTOOLS.ORG.

6.10 The PURCHASER shall ensure the proper and safe handling, storage and use of the ANTIBODY and MODIFIED ANTIBODY in accordance with all applicable laws and regulations.

7. LIMITATIONS OF LIABILITY

7.1 CANCERTOOLS.ORG will use its reasonable endeavors to replace any ANTIBODY that it is proved to the reasonable satisfaction of CANCERTOOLS.ORG to be not viable, provided that notice of such defect is given in writing to CANCERTOOLS.ORG within fourteen (14) days of receipt of the ANTIBODY. If CANCERTOOLS.ORG is unable to replace the ANTIBODY within a reasonable period CANCERTOOLS.ORG shall refund to the PURCHASER the price paid in respect of such ANTIBODY and this contract shall terminate in so far as it relates to such ANTIBODY. These obligations shall not however apply where:

7.1.1. the ANTIBODY has been altered in any way after delivery to PURCHASER; or
7.1.2. the PURCHASER has failed to observe any storage, use or handling practices relevant to the ANTIBODY commonly practiced in research laboratories; or
7.1.3. the PURCHASER has failed to notify CANCERTOOLS.ORG of any defect or suspected defect within seven (7) working days of the same coming to the knowledge of the PURCHASER; or
7.1.4. the PURCHASER is in breach of this contract.

7.2 ANTIBODY is experimental in nature and accordingly, CANCERTOOLS.ORG makes no representations, and gives no warranty or undertaking in relation to it. CANCERTOOLS.ORG hereby excludes any condition, warranty, stipulation or other term whether express or implied, statutory or otherwise which, but for such exclusion, would or might exist in favour of the PURCHASER. Without limiting the foregoing, CANCERTOOLS.ORG does not give or make any representation, warranty or condition that ANTIBODY is uncontaminated, safe, non-hazardous or non-toxic, or as to the testing of the ANTIBODY whether for the presence or absence of pathogens or otherwise, or that the possession or use of ANTIBODY will not infringe any patent or other right owned by any third party.

7.3 No data, specifications or other information issued by CANCERTOOLS.ORG or contained in any catalogue, information sheet or other promotional material will form part of this contract nor be regarded as a warranty or representation relating to the ANTIBODY. Any such information is given by way of guidance only and the PURCHASER hereby agrees that it does not in any way rely on any such description when entering this contract.

7.4 Save as provided in Clause 7.1 and except to the extent such liability cannot lawfully be excluded neither CANCERTOOLS.ORG, CR-UK nor any other originator of the ANTIBODY shall have any liability for any loss or damage of any kind whatsoever, whether direct or consequential and including without limitation any loss of profit, howsoever the same may arise under or in connection with this contract and whether in contract or caused directly or indirectly by any negligence or other tortious act of CANCERTOOLS.ORG, CR-UK, SOURCE or any other originator of the ANTIBODY in connection with or arising out of the supply, failure to supply, use, keeping or transportation of ANTIBODY or in connection with any statement given or made (or advice not given or made) by or on behalf of CANCERTOOLS.ORG or CR-UK.

8. INDEMNITY

8.1 The PURCHASER assumes all risks of harm, loss or damage arising directly from or in relation to the ANTIBODY and/or MODIFIED ANTIBODY after delivery or arising from or in relation to the handling, storage, use or possession of the ANTIBODY and/or MODIFIED ANTIBODY by the PURCHASER or by anyone to whom the PURCHASER or its representatives may make it available. The PURCHASER shall indemnify and hold harmless CANCERTOOLS.ORG, CR-UK, SOURCE and any other originator of the ANTIBODY, against all Claims and Losses arising from the handling, storage, use or possession of ANTIBODY and/or MODIFIED ANTIBODY by the PURCHASER or anyone to whom the PURCHASER or its representatives may make it available, including, without limitation, injury to the PURCHASER, PURCHASER’s employees or third parties except for Claims and Losses to the extent arising from CANCERTOOLS.ORG, CR-UK, SOURCE and any other originator of the ANTIBODY’s gross negligence or wilful misconduct. Neither Party shall be liable under or in connection with this contract for any indirect or consequential loss or damage of any kind howsoever arising. For the purposes of this Clause, “Claims” shall include all demands, claims, proceedings, penalties, fines and liability (whether criminal or civil, in contract, tort or otherwise) and “Losses” shall include all losses, damages, legal costs and other expenses of any nature whatsoever.

8.2 With respect to any ANTIBODY where the SOURCE is Johns Hopkins University (JHU): the PURCHASER shall, protect, defend, and indemnify JHU, The Johns Hopkins Hospital, The Johns Hopkins Health System Corporation, and their affiliated entities, their present and former trustees, officers, innovators, agents, faculty, employees and students (JHU Indemnitees) from and against any claims, losses, or damages of third parties (i) arising from or related to any act or omission of PURCHASER, (ii) caused by or arising from the ANTIBODY and/or MODIFIED ANTIBODY, or (iii) or allegedly arising as a consequence of PURCHASER’s performance of, or exercise of rights under, this contract. PURCHASER shall defend the JHU Indemnitees against any claim subject to this Clause 8.2 with counsel chosen at the sole discretion of PURCHASER but reasonably acceptable to JHU, and shall hold the JHU Indemnitees harmless as against any judgments, fees, expenses, or other costs arising from or incidental to any such lawsuit, claim, demand or other action, whether or not any JHU Indemnitee is named as a party defendant in any such lawsuit and whether or not the JHU indemnitees are alleged to be negligent or otherwise responsible for any injuries to persons or property. Indemnification in this Clause 8.2 excludes (i) claims arising solely from the practice by JHU of its retained rights; (ii) claims arising solely from the negligent use or administration by a JHU Indemnitee of the ANTIBODY and/or MODIFIED ANTIBODY (but any related claim of product liability or indemnitee negligence shall remain subject to indemnification).

9. FORCE MAJEURE

9.1 CANCERTOOLS.ORG shall not be deemed to be in breach of this contract or otherwise liable to the PURCHASER for any failure or delay in performing its obligations under this contract due to any cause beyond its reasonable control, which expression shall include, without limitation, governmental action, labour disputes involving the workforce or part thereof of CANCERTOOLS.ORG or CR-UK and Act of God.

10. TERMINATION

10.1 Either party may terminate this contract forthwith by notice in writing if the other:

10.1.1 is in breach of this contract and, in the case of a breach capable of remedy, has failed to remedy the breach within fourteen (14) days of the receipt of a request in writing from the party not in breach to remedy the breach;
10.1.2 has a receiver, manager, administrator or administrative receiver appointed of its assets or income or part thereof or has passed a resolution for its winding-up or has a petition presented to any court for its winding-up or for an administration order.

11. MISCELLANEOUS

11.1 The PURCHASER shall not be entitled to assign the benefit or delegate the burden of this contract without CANCERTOOLS.ORG’s prior written consent.

11.2 Nothing contained in this contract shall be construed as establishing or implying any partnership or joint venture between the PURCHASER and CANCERTOOLS.ORG and/or CR-UK.

11.3 This contract shall be governed by and construed in accordance with English law. Each party agrees that the courts of the main place of business of the defendant shall have exclusive jurisdiction to settle any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with this contact or its subject matter or formation.

11.4 CANCERTOOLS.ORG and JHU have an agreement in place that allows CANCERTOOLS.ORG to undertake commercial exploitation of certain JHU research reagents. With respect to any ANTIBODY where the SOURCE is JHU: JHU is a third-party beneficiary under this contract and will have the right to audit and enforce the terms within this contract.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.